# 24-hr Intraocular Pressure Control With SIMBRINZA ®

> **NCT02770248** · PHASE4 · COMPLETED · sponsor: **Alcon Research** · enrollment: 162 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT02770248
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-23
- **Primary completion:** 2017-01-14
- **Final completion:** 2017-01-14
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2018-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02770248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02770248, "24-hr Intraocular Pressure Control With SIMBRINZA ®". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02770248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*